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Antagonists of Calcium Fluxes and Calmodulin Block
Activation of the p21-Activated Protein Kinases in
Neutrophils1
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Dwight Robinson,§ and John A. Badwey2*¶
Neutrophils stimulated with fMLP or a variety of other chemoattractants that bind to serpentine receptors coupled to heterotri-
meric G proteins exhibit rapid activation of two p21-activated protein kinases (Paks) with molecular masses of ;63 and 69 kDa
(g- and a-Pak). Previous studies have shown that products of phosphatidylinositol 3-kinase and tyrosine kinases are required for
the activation of Paks. We now report that a variety of structurally distinct compounds which interrupt different stages in
calcium/calmodulin (CaM) signaling block activation of the 63- and 69-kDa Paks in fMLP-stimulated neutrophils. These antag-
onists included selective inhibitors of phospholipase C (1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-
2,5-dione), the intracellular Ca21 channel (8-(N,N-diethylamino)-octyl-3,4,5-trimethoxybenzoate), CaM (N-(6-aminohexyl)-5-
chloro-1-naphthalenesulfonamide; N-(4-aminobutyl)-5-chloro-1-naphthalenesulfonamide; trifluoperazine), and CaM-activated
protein kinases (N-[2-(N-(chlorocinnamyl)-N-methylaminomethyl)phenyl]-N-[2-hydroxyethyl]-4-methoxybenzenesulfonamide).
This inhibition was dose-dependent with IC50 values very similar to those that interrupt CaM-dependent reactions in vitro. In
contrast, less active analogues of these compounds (1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-2,5-pyrro-
lidinedione; N-(6-aminohexyl)-1-naphthalenesulfonamide; N-(4-aminobutyl)-1-naphthalenesulfonamide; promethazine; 2-[N-(4-
methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzyl-amine]) did not affect activation of Paks in these cells.
CaM antagonists (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide; trifluoperazine), but not their less-active analogues (N-
(6-aminohexyl)-1-naphthalenesulfonamide; promethazine), were also found to block activation of the small GTPases Ras and Rac
in stimulated neutrophils along with the extracellular signal-regulated kinases. These data strongly suggest that the Ca21/CaM
complex plays a major role in the activation of a number of enzyme systems in neutrophils that are regulated by small
GTPases. The Journal of Immunology, 2001, 166: 2643–2650.
N eutrophils stimulated with fMLP or a variety of otherchemoattractants that couple to heterotrimeric G pro-teins exhibit rapid activation of a large number of pro-
tein kinases that participate in the functional responses of these
cells. These protein kinases include two p21-activated protein ki-
nases (Paks)3 with molecular masses of 63 and 69 kDa (g- and
a-Pak; Refs. 1–5) and certain mitogen-activated protein kinase
(MAPK) cascades (e.g., extracellular signal-regulated kinases
(ERK-1/2), p38-MAPK; Refs. 6–10). Paks are Ser/Thr protein ki-
nases that undergo autophosphorylation/activation upon interact-
ing with the active (GTP-bound) forms of the small GTPases(p21)
Rac or Cdc42 (11). Activation of the Paks in neutrophils can be
blocked by inhibitors of heterotrimeric G proteins (pertussis toxin)
(2, 5), phosphatidylinositol 3-kinase (PI 3-K; i.e., wortmannin, LY
294002) (12), and tyrosine kinases (13, 14). Paks or Pak-like ki-
nases contain binding sites for the bg-subunits of complex G pro-
teins (15), guanine nucleotide exchange factors (GEF; i.e., Pak-
interacting exchange factors) (16), and adaptor proteins (Nck) (17,
18). Paks may directly interact with the cytoskeleton through p95
paxillin-kinase linker, which binds directly to both Pak-interacting
exchange factors and the focal adhesion adaptor protein paxillin
(19). Thus, Paks may be capable of integrating messengers from a
number of signal transduction pathways.
Paks can participate in a broad range of cellular events that
include rapid cytoskeletal responses, activation/potentiation of
several distinct MAPK cascades and apoptosis (for review see Ref.
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20 and 21). Recent studies have implicated Pak in the activation of
NF-kB in macrophages (22), tumor growth (23) and the pathogen-
esis of HIV (24, 25). Paks can also catalyze the phosphorylation in
vitro of both the 47- and 67-kDa subunits of the superoxide (O22)-
generating system of phagocytic leukocytes (NADPH-oxidase) (5,
26). However, it is not known whether Paks participate in the
phosphorylation of these oxidase subunits in vivo.
Recent studies have shown that heterotrimeric G proteins can ac-
tivate Ras, Src family tyrosine kinases, and the extracellular signal
regulated kinases (ERKs-1/2) through a variety of signal transduction
pathways (27, 28). One such pathway contains phosphatidylinositol-
specific phospholipase C (PI-PLC) and the Ca21/calmodulin (CaM)
complex as major components in the activation of Src and Ras (28).
We have recently demonstrated that D-erythro-sphingosine blocks
activation of the 63- and 69-kDa Paks in neutrophils if added to the
cells either before or after stimulation with fMLP (29). Interest-
ingly, D-erythro-sphingosine can inhibit a number of enzymes ac-
tivated by the Ca21/CaM complex (30).
In this paper, we describe the effects of selective antagonists of
PLC, the intracellular Ca21 channel, the Ca21/CaM complex, and
CaM-activated protein kinases (CaM-PK) on the activation of Paks
in neutrophils. The data indicate that the Ca21/CaM complex has
a major role in regulating the Paks in these cells along with other
enzyme systems activated by small GTPases.
Materials and Methods
Materials
N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7); N-(6-amino-
hexyl)-1-naphthalenesulfonamide (W-5); N-(4-aminobutyl)-5-chloro-1-naphtha-
lenesulfonamide (W-13); N-(4-aminobutyl)-1-naphthalenesulfonamide (W-12);
1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-1H-pyrrole-2,5-di-
one (U-73122); 1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl]-
2,5-pyrrolidinedione (U-73343); 8-(N,N-diethylamino)-octyl-3,4,5-trimethoxy-
benzoate (TMB-8); N-[2-(N-(chlorocinnamyl)-N-methylaminomethyl)phenyl]-N-
[2-hydroxyethyl]-4-methoxybenzenesulfonamide (KN-93); and 2-[N-(4-meth-
oxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzyl-amine] (KN-
92) were purchased from Calbiochem (La Jolla, CA). Purified mouse mAbs
to human Ras was obtained from PharMingen/Transduction Laboratories
(San Diego, CA). A mouse mAb to full-length human Rac was purchased
from Upstate Biotechnology (Lake Placid, NY). Affinity-purified, rabbit
polyclonal Abs that recognized only the active (doubly phosphorylated)
forms of MAP/ERK kinase (MEK)1 and MEK2 (phospho-MEK-1/2
(Ser217/Ser221) Ab) were obtained from New England Biolabs (Beverly,
MA). Affinity-purified, rabbit polyclonal Abs that recognized only the ac-
tive (doubly phosphorylated) forms of ERK (p44/ERK1 and p42/ERK2)
were obtained from Promega (Madison, WI). Affinity-purified rabbit poly-
clonal Abs that recognized both the phosphorylated and nonphosphorylated
forms of ERK (p44/42 (ERK-1/2) MAPK Abs) were also purchased from
New England Biolabs. Goat anti-rabbit IgG labeled with HRP, goat anti-
mouse IgG labeled with HRP, a Super Signal substrate Western blotting kit
for luminol-enhanced chemiluminescence, and an ImmunoPure binding/
elution buffer system for stripping and reblotting Western blots were pur-
chased from Pierce (Rockford, IL). Sources of all other materials are de-
scribed elsewhere (1–3).
Preparation of neutrophils
Guinea pig peritoneal neutrophils were prepared as described previously
(31). These preparations contained .90% neutrophils with viabilities al-
ways .90%.
Detection of renaturable protein kinases (Paks) in
polyacrylamide gels
Paks and certain other protein kinases were detected directly in gels by
their ability to undergo renaturation and catalyze the phosphorylation of a
peptide substrate fixed within a gel that corresponds to amino acid residues
297–331 of the 47-kDa protein component of the phagocyte oxidase (p47-
phox). This technique was performed as described elsewhere (2) except the
amount of cells was reduced to 3 3 106/ml.
Detection of activated Rac and Ras
Activated forms of Rac or Ras were measured in neutrophil lysates by their
ability to bind specifically to GST-fusion proteins containing the Cde42/
Rac interactive binding (CRIB) domain of Pak1b (crib domain, amino acid
residues 56–227) (GST-Pak-CRIB) or the Ras-binding domain of Raf
(GST-Raf-RBD) coupled to glutathione agarose beads (32, 33). The beads
were subsequently isolated, washed, and subjected to SDS-PAGE as de-
scribed previously (32, 33). Specific binding of Rac to the GST-Pak crib
fusion protein was determined by Western blotting with a specific Ab to
this small GTPase. Conditions for Western blotting are described below.
Fusion proteins were prepared as described previously (32, 34).
Immunoblotting/detection of activated ERKs and MEK in
stimulated neutrophils
Neutrophils (3 3 106/ml) were stimulated and lysed as described (1). Ali-
quots of these samples were separated by SDS-PAGE (35 mg/lane) on
9.0% (v/v) polyacrylamide slab gels and transferred electrophoretically to
Immobilon-P membranes as described (1). Activated ERK and MEK were
assayed by Western blotting with Abs that recognized only the activated
(doubly phosphorylated) forms of these kinases (35). Activated kinases and
the small GTPases were visualized with a luminol-enhanced chemilumi-
nescence detection system (Pierce), which monitored the activity of HRP
bound to the secondary Ab (35). Membranes were incubated with the pri-
mary Ab against 1.0 mg/ml Rac or Ras (1:500 dilution) for 1 h at room
temperature. All other Ab dilutions and conditions for Western blotting are
detailed by Huang et al. (14).
In certain experiments (Fig. 6), products of the chemiluminescence de-
tection system were removed by washing the membranes two times (10
min/wash) with TBST (20 mM Tris-HCl (pH 7.4) containing 150 mM
NaCl and 0.01% (v/v) Tween 20). These blots were then reprobed with a
different Ab as described above so that both Ags could be visualized si-
multaneously (Ref. 35; Fig. 6). At the end of these experiments, both the
immunodetection system and the bound Abs were removed from the blot
by incubating the membranes with ImmunoPure elution buffer (Pierce) for
30–60 min at room temperature followed by two washes with TBST. The
blots were then stained with an Ab that recognized both the phosphorylated
and nonphosphorylated forms of ERK to confirm that equal amounts of
protein were present in each lane of the gel.
Miscellaneous procedures
O22 release from neutrophils was measured as described previously (2).
Analysis of data
Unless otherwise noted, all of the autoradiographic observations were con-
firmed in at least three separate experiments performed on different cell
preparations. The numbers of observations (n) are also based on different
cell preparations.
Results
Effects of Ca21/CaM antagonists on activation of the Paks in
neutrophils
Neutrophils stimulated with the chemoattractant fMLP exhibit
rapid activation of two Paks with molecular masses of ;63 and 69
kDa along with two unidentified renaturable protein kinases with
masses of ;49 and 40 kDa (Fig. 1; Refs. 2 and 4). These kinases
can be detected directly in gels by their ability to undergo rena-
turation and catalyze the phosphorylation of a peptide substrate
fixed within a gel. Positions of the protein kinases are visualized by
autoradiography after exposure of the gel to [g-32P]ATP (2). The
peptide used corresponds to amino acid residues 297–331 of p47-
phox and contains several of the phosphorylation sites of this
protein.
Certain naphthalenesulfonamides (W-7, W-13) have been de-
signed as selective antagonists of CaM (36). The order of potency
of these compounds in vitro is W-7 . W-13 with the unchlorinated
analogues of these molecules (W-5, W-12) being considerably less
active (36). Thus, W-5 and W-12 serve as excellent controls for
evaluating nonspecific cellular effects of W-7 and W-13, respec-
tively. Treatment of neutrophils with 50 mM W-7 for 5.0 min
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before stimulation with 1.0 mM fMLP completely blocked activa-
tion of the 63- and 69-kDa Paks along with the 49- and 40-kDa
kinases (Fig. 1c). In contrast, 50 mM W-13 was only partially
effective in blocking activation of these kinases and 50 mM W-5
lacked activity (Fig. 1, d and e). Increasing the concentration of
W-13 to 100 mM markedly reduced activation of the 63- and 69-
kDa Paks, whereas the unchlorinated derivative W-12 was inactive
even at this concentration (Fig. 1, f and g).
Fig. 2 presents dose-response data for blockade of Pak activa-
tion by W-7 and several other structurally diverse, selective inhib-
itors that block different aspects of Ca21 signaling. The antagonists
employed consisted of inhibitors of phospholipase C (PLC) (U-
73122) (37), the intracellular Ca21channel (TMB-8) (38), the
Ca21/CaM complex (trifluoperazine (TFP)) (39), and Ca21/CaM-
activated protein kinases (KN-93) (40). These compounds were
chosen, in part, because of the availability of less active analogues
to monitor possible nonspecific effects of the antagonists on cells.
The less-active analogues of TFP, U-73122, and KN-93 are
promethazine (PMZ), U-73343, and KN-92, respectively (37, 39,
40). All of the antagonists listed above blocked activation of the
63- and 69-kDa Paks in fMLP-stimulated neutrophils in a dose-
dependent manner at their effective pharmacological doses (Refs.
37–42; see below).
The decreases in Pak activity with these compounds were esti-
mated by densitometry performed on x-ray films by comparing the
peak heights of the bands in lane b with those in lanes c or d in
Figs. 1 and 2. Treatment of neutrophils with 50 mM W-7, 15 mM
TFP, 1.0 mM U-73122, 200 mM TMB-8, or 50 mM KN-93 before
stimulation with 1.0 mM fMLP for 15 s reduced the content of 32P
in the 63- and 69-kDa bands by 93 6 3% and 92 6 3%, 87 6 14%
and 82 6 17%, 83 6 12% and 84 6 10%, 78 6 14% and 73 6
25%, and 72 6 5% and 73 6 9% (SD, n 5 3–5), respectively. In
contrast, similar treatment of the cells with 50 mM W-5, 15 mM
PMZ, 1.0 mM U-73343, or 50 mM KN-92 did not significantly
reduce the content of 32P in the 63- or 69-kDa bands (data not
shown; n 5 3–5).
Addition of 50 mM W-7, 100 mM W-13, 15 mM TFP, 1.0 mM
U-73122, 200 mM TMB-8, or 100 mM KN-93 to the phosphory-
lation step of the “in gel” renaturation assay with the p47-phox
peptide substrate did not affect this reaction (n 5 2; data not
shown). These data strongly indicate that these antagonists did not
interact with the 63- and 69-kDa Paks themselves, but on upstream
components involved in the activation of the kinases (see Discus-
sion). The concentrations of inhibitors and conditions used did not
affect cell viability, as measured by the exclusion of trypan blue or
by the release of lactate dehydrogenase from the cells (data not
shown; Ref. 37, 38, and 41).
Neutrophils stimulated with 1.0 mM fMLP release large quan-
tities of O22 (i.e., 46 6 9 nmol O22/min/107 cells) as a result of
the activation of the NADPH-oxidase system (2). Compounds
W-7, TFP, U-73122, and TMB-8 are known to inhibit O22 release
from stimulated neutrophils (37, 38, 41). The concentrations of
FIGURE 1. Effects of Ca21/CaM antagonists on activation of the Paks
in neutrophils. Paks were assayed in neutrophil lysates by their ability to
undergo renaturation and catalyze phosphorylation of the p47-phox peptide
fixed within a gel as described in Materials and Methods. Cells were
treated with the inhibitors at the concentrations specified for 5.0 min at
37°C and then stimulated with 1.0 mM fMLP for 15 s. Lane a is for
unstimulated cells not treated with an inhibitor. Lanes b1 and b2 are for
two different preparations of stimulated cells not treated with an inhibitor.
The positions of the 69- and 63-kDa Paks are designated by a filled ar-
rowhead and a solid arrow, respectively. The renaturable 49- and 40-kDa
kinases are marked by an open arrowhead and a dashed arrow,
respectively.
FIGURE 2. Effects of different concentrations of antagonists on activa-
tion of the Paks in neutrophils. Neutrophils were treated with various
amounts of W-7 (A), TFP (B), U-73122 (C) and TMB-8 (E) for 5.0 min or
KN-93 (D) for 30 min and then stimulated with 1.0 mM fMLP for 15 s.
Paks were monitored by their ability to undergo renaturation and catalyze
phosphorylation of the p47-phox peptide fixed within a gel as described in
Materials and Methods. In all cases, lane a is for cells treated with 0.25%
(v/v) DMSO for 15 s (unstimulated neutrophils) and lane b is for cells
stimulated with 1.0 mM fMLP for 15 s. The positions of the 69- and 63-
kDa Paks are designated by an arrowhead and arrow, respectively.
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these drugs that blocked O22 release (Fig. 3) were very similar to
those that inhibited activation of the 63- and 69-kDa Paks (Fig. 2).
In contrast, treatment of neutrophils with (50–100 mM) KN-93 for
15–30 min at 37°C before stimulation with 1.0 mM fMLP had no
effect on O22 release (n 5 4; data not shown) even though this
antagonist was effective against Pak (Fig. 2D).
Effects of Ca21/CaM antagonists on the activation of Rac in
stimulated neutrophils
The fact that a variety of antagonists of Ca21 signaling events were
equally effective in blocking activation of the Paks and NADPH-
oxidase complex in neutrophils suggested that these inhibitors
might be effecting a common component of these systems. As
noted above, activated Rac (GTP-bound) can trigger autophos-
phorylation/activation of Pak (11). Rac-GTP is also an obligatory
subunit of the NADPH-oxidase system (43). The effects of CaM
antagonists on the activation of Rac in fMLP-stimulated neutro-
phils were examined with a fusion protein containing the p21-
binding domain of Pak that binds only the GTP-bound form of Rac
(33, 44, 45). Rac exhibited maximal activation within 15 s of cell
stimulation, followed by significant inactivation at 3.0 min (Fig.
4A). This pattern of activation was virtually identical with that
exhibited by the 63- and 69-kDa Paks in fMLP-stimulated neutro-
phils (Fig. 4B; Refs. 2 and 4). Incubation of neutrophils with 50
mM W-7 or 15 mM TFP for 5.0 min at 37°C before stimulation
with 1.0 mM fMLP for 15 s blocked activation of Rac, whereas 50
mM W-5 or 15 mM PMZ did not effect this process (Fig. 4C). This
treatment of neutrophils with W-7, W-5, TFP, and PMZ reduced
activation of Rac by 91 6 5%, 9 6 10%, 97 6 5%, and 36 6 8%
(SD, n 5 3), respectively. Treatment of neutrophils with 200 nM
wortmannin for 10 min at 37°C before stimulation with 1.0 mM
fMLP for 15 s reduced the activation of Rac by 68 6 9% (range,
n 5 2) (Fig. 2D) as reported in previous studies (33, 44). In con-
trast, treatment of neutrophils with 50 mM KN-93 for 30 min at
37°C before stimulation with 1.0 mM fMLP for 15 s did not effect
the activation of Rac (n 5 2; Fig. 2D) .
Effects of Ca21/CaM antagonists on the activation of Ras and
the extracellular regulated kinases (ERKs) in neutrophils
Previous studies have shown that CaM antagonists can either block
(27, 28) or prolong (46) the activation of ERKs in various cell
types. Because ERKs are effector proteins for the small GTPase
Ras, we examined the effects of CaM antagonists on the activation
of Ras, MEK, and ERK in neutrophils (Figs. 5 and 6). Previous
studies have shown that neutrophils stimulated with fMLP exhibit
rapid activation of Ras (8) and ERK-1/2 (6–10, 35). We confirmed
the activation of Ras in guinea pig neutrophils stimulated with
fMLP using a fusion protein that contained the Ras binding do-
main of Raf coupled to glutathione agarose beads. This fusion
protein binds only the activated, GTP-bound form of Ras (32). Ras
exhibited maximal activation within 15–30 s followed by signifi-
cant inactivation at 1.0–3.0 min (Fig. 5A). This activation of Ras
was insensitive to 200 nM wortmannin (n 5 3; data not shown).
Treatment of neutrophils with 50 mM W-7 or 15 mM TFP for 10
min before stimulation with 1.0 mM fMLP for 30 s markedly re-
duced the activation of Ras, whereas compounds W-5 (50 mM) and
PMZ (15 mM) had little or no effect on this reaction (Fig. 5B). This
treatment with 50 mM W-7, 50 mM W-5, 15 mM TFP, or 15 mM
PMZ reduced the activation of Ras by 80 6 18%, 10 6 9%, 97 6
5%, and 16 6 27% (SD, n 5 3), respectively.
Activation of ERK-1/2 and MEK in neutrophils was monitored
with Abs that recognized only the activated (doubly phosphory-
lated) forms of these kinases. p42-ERK, a small amount of p44-
ERK, and MEK undergo a pronounced activation in neutrophils at
;1.0–3.0 min after stimulation of these cells with fMLP (35).
Previous studies have shown that MEK-2 is the predominant iso-
form of this kinase in human neutrophils and undergoes activation
in fMLP-stimulated cells (47). Data presented in Fig. 6 demon-
strate the effects of CaM antagonists on the activation of ERK-1/2
and MEK in neutrophils. The cells were incubated with the antag-
onists for 10 min at 37°C and then stimulated with 1.0 mM fMLP
for 3.0 min. A single blot was first stained for activated ERKs (Fig.
6A) and then stained again for activated MEK (Fig. 6B). As was
the case with Ras, 50 mM W-7 and 15 mM TFP markedly reduced
the activation of ERKs and MEK in these cells whereas 50 mM
W-5 and 15 mM PMZ had little or no effect. Visualization of MEK
by the chemiluminescence detection system required a longer re-
action time than that needed for p42-ERK (Fig. 6A), which re-
sulted in the p42-ERK band being over-exposed in Fig. 6B. Treat-
ment of the cells with 50 mM W-7, 50 mM W-5, 15 mM TFP, and
15 mM PMZ reduced the activation of p42-ERK by 96 6 4%,
21 6 10%, 100 6 0%, and 19 6 26% (n 5 2–3), respectively.
These data were calculated by densitometry from blots stained for
p42-ERK alone as shown in Fig. 6A. Thus, the Ca2/CaM complex
plays a major role in activating the small GTPases Ras and Rac in
neutrophils along with their downstream effectors (e.g., Paks,
NAPDH-oxidase, ERKs).
Discussion
The overall pathway that triggers activation of Rac and Pak in
neutrophils is largely unknown. Subunits of complex G proteins
coupled to the fMLP receptor are involved in triggering activation
of PI-PLC and PI 3-K in neutrophils (48–51). Inositol(1,4,5)-
trisphosphate, a product of PI-PLC, promotes a transient increase
in intracellular Ca21 in neutrophils by triggering the release of this
cation from intracellular storage depots (48). In this paper, we
report that a variety of structurally diverse, selective antagonists of
PLC, the intracellular Ca21 channel, CaM and CaM-PK block ac-
tivation of the 63- and 69-kDa Paks. Antagonists of CaM were also
found to block activation of Rac and Ras in neutrophils along with
FIGURE 3. Effects of different concentrations of antagonists on O22
release from neutrophils. Neutrophils were treated with various amounts of
U-73122 (M), TFP (L), W-7 (E) and TMB-8 () for 5.0 min at 37°C and
then stimulated with 1.0 mM fMLP. O22 was assayed as referenced in
Materials and Methods. Data points represent mean values of two to three
different experiments.
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other downstream targets of these small GTPases. The significance
of these and other novel observations are discussed below.
It is not possible to employ the techniques of molecular biology
to investigate the involvement of the Ca21/CaM complex in Pak
activation in primary neutrophils because these cells are short-
lived. Therefore, particular care was taken to employ structurally
distinct antagonists, which blocked different stages in triggering
the increase in cytosolic Ca2 and the subsequent target/effector
proteins. The choice was also restricted to those compounds for
which less active analogues were available. The order of effec-
tiveness of the CaM antagonists in blocking activation of Paks
(i.e., TFP . W-7 . W-13 . PMZ, W-5, and W-12) (Figs. 1 and
2) was identical with that reported for CaM-dependent enzymes in
vitro (39). Although TFP and W-7 can also inhibit protein kinase
C (PKC) at high concentrations (52), PKC is not involved in ac-
tivating the Paks in neutrophils (1, 4, 5). Moreover, the concen-
trations of TFP and W-7 required for blockade of Pak activation
(i.e., ;10 and 25 mM, respectively) (Fig. 2) were very similar to
that observed for CaM-dependent processes (39) and severalfold
less than that required to inhibit PKC (52). The IC50 values for
TFP, W-7, W-5, and PMZ blocking the CaM mediated activation
of cAMP phosphodiesterase in vitro are 2–10, 28, 240, and 200–
340 mM, respectively (39). The concentrations of TFP, W-7,
U-73122, KN-93, and TMB-8 routinely used to block CaM, CaM,
PLC, CaM-PK, and the intracellular Ca2a channel in vivo are ;10,
35, 1.0, 20, and 100–300 mM, respectively (37–39, 42). Each of
these antagonists were effective at blocking activation of the Paks
in neutrophils at these doses (Fig. 2). In contrast, the antagonists
W-7 (50 mM) and TFP (15 mM) did not effect the increases in
FIGURE 4. Activation of Rac (A) and Pak (B) in stimulated neutrophils.
Effects of Ca21/CaM antagonists (C) and other inhibitors (D) on the acti-
vation of Rac. A, Time-course for the activation of Rac in neutrophils
stimulated with 1.0 mM fMLP. Activation of Rac was measured in a pull-
down assay with a GST-Pak-CRIB fusion protein as described in Materials
and Methods. Cells were incubated for 5.0 min at 37°C in the standard
assay medium and then stimulated with fMLP (1.0 mM) for the times
indicated. The position of Rac is designated by an arrow. The location of
the GST-Pak-CRIB fusion protein is designated by an arrowhead. B, Time
course for the activation of the 63- and 69-kDa Paks in neutrophils stim-
ulated with 1.0 mM fMLP. Paks were monitored by their ability to undergo
renaturation and catalyze phosphorylation of the p47-phox peptide fixed
within a gel as described in Materials and Methods. Lanes a–g are for the
same assay conditions as in A. The positions of the 69- and 63-kDa Paks
are designated by a filled arrowhead and an arrow, respectively. The pro-
tein kinase that undergoes activation at time points $ 1.0 min (dotted
arrow) is p90RSK2 . C, Effects of various antagonists on the activation of
Rac. Cells were treated with the inhibitors for 5.0 min at 37°C and then
stimulated with 1.0 mM fMLP for 15 s. Lane a is for unstimulated neu-
trophils. Lane b is for stimulated cells. Lanes c–f are for stimulated neu-
trophils treated with the following: 50 mM W-7 (c), 50 mM W-5 (d), 15
mM TFP (e), and 15 mM PMZ (f). D, Effects of various antagonists on the
activation of Rac. Cells were incubated at 37°C with or without inhibitors
for 10 min (lanes a–c) or 30 min (lanes d–g) and then stimulated with 1.0
mM fMLP for 15 s. Lanes a and d are for unstimulated cells. Lanes b and
FIGURE 5. Effects of Ca21/CaM antagonists on activation of Ras in
neutrophils. Activation of Ras was measured in a pull-down assay with a
GST-Raf-RBD fusion protein as described in Materials and Methods. A,
Time-course for the activation of Ras in neutrophils stimulated with 1.0
mM fMLP. Cells were incubated for 5.0 min at 37°C in the standard assay
medium and then stimulated with fMLP for the times indicated. B, Effects
of various antagonists on the activation of Ras. Cells were treated with the
inhibitors for 5.0 min at 37°C and then stimulated with 1.0 mM fMLP for
30 s. Lane a is for unstimulated neutrophils. Lane b is for stimulated cells.
Lanes c–f are for stimulated cells treated with the following: 50 mM W-7
(c), 50 mM W-5 (d), 15 mM TFP (e), and 15 mM PMZ (f). The position of
activated Ras is designated by the arrow.
e are for stimulated cells. Lanes c, f, and g are for stimulated cells treated
with the following: 200 nM wortmannin (c), 50 mM KN-93 (f), and 50 mM
KN-92 (g).
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Ca21 permeability or cytosolic Ca21 that occur in fMLP-stimu-
lated neutrophils (Refs. 38 and 53; data not shown), which indi-
cates that these inhibitors are selective for certain pathways and do
not have a general disruptive effect on the fMLP-receptor.
The GEF that promotes activation of Rac (and hence Pak) in
fMLP-stimulated neutrophils is blocked by antagonists of PI 3-K
and tyrosine kinases (33, 44). Only the g-isoform of PI 3-K is
activated when neutrophils are stimulated with fMLP (49–51).
Unlike other isoforms of PI 3-K, the g-isoform is directly activated
by bg-subunits of complex G proteins and is not activated by
binding to tyrosine phosphorylated proteins (49–51). Thus, the
tyrosine kinase involved in the activation of Rac is not likely to be
“upstream” of PI 3-K. One possible explanation for these data is
that the relevant GEF requires both products of PI 3-K and tyrosine
phosphorylation for activation (Fig. 7). Interestingly, Vav, a GEF
for Rac, undergoes enhanced phosphorylation/activation by a Src-
related kinase when bound to PIP3 (54). Location of Vav or a
similar GEF upstream of Rac would account for the sensitivity of
the Pak stimulatory pathway to pertussis toxin, wortmannin, and
herbimycin.
How does CaM fit into the scenario described above? Although
the answer to this question is not yet known, a modest amount of
speculation may be appropriate here. Certain receptors coupled to
pertussis-toxin-sensitive G proteins can trigger activation of Src-
related tyrosine kinases, Ras and ERK through a stimulatory path-
way that contains PI-PLC and CaM (27, 28). Fig. 7 presents a
modified portion of that model (28). The ability of CaM antago-
nists to block activation of Ras and ERK in neutrophils (Figs. 5
and 6) is consistent with a similar stimulatory pathway being
present in these cells. Addition of a GEF to this pathway, which is
synergistically activated by PI 3-K and tyrosine phosphorylation as
described above, will account for all of the data presented herein
and in earlier publications (2–5, 12–14). This modified model pre-
dicts that the Ca21/CaM complex is required for activation of a
tyrosine kinase that lies upstream of the GEF for Rac. Thus, most
(see below) Ca21/CaM antagonists block activation of Pak (Figs.
1 and 2) by preventing activation of Rac (Fig. 4). Activation of the
Src-related kinase Lyn by a mechanism dependent upon Ca2/CaM
has been described in macrophages (55). This scheme can also
explain why agonists that only increase intracellular Ca2 in neu-
trophils (thapsigargin, ionophore A23187) do not trigger activation
of Pak (1, 2, 4) because bg-subunits of complex G proteins are
also required to effectively activate PI 3-K and thus Rac in these
cells. Activation of Tiam1, a GEF for Rac, is catalyzed by
CaM-PK and blocked by KN-93 in fibroblasts (42). The inability
of KN-93 to block activation of Rac in fMLP-stimulated neutro-
phils (Fig. 4D) suggests that Tiam1 is either not involved in this
reaction in neutrophils or its activation under these circumstances
does not require CaM-PK.
In contrast to studies reported in this paper and elsewhere (33,
44), a previous paper has reported that activation of Rac in human
neutrophils is insensitive to an antagonist of PI 3-K (10 mM
LY294002) and genistein (45). The “pull-down” assay used to
monitor activated Rac only measures the fraction of this GTPase
that is accessible to the fusion protein and may not detect mem-
brane associated Rac or Rac that forms high affinity complexes
FIGURE 6. Effects of Ca21/CaM antagonists on acti-
vation of the ERKs (A) and MEK (B) in stimulated neu-
trophils. Activation of ERKs (A, arrows) and MEK (B,
filled arrowhead) was monitored by Western blotting
with Abs that only recognized the activated (doubly phos-
phorylated) forms of these kinases. Stimulation of the
cells and Western blotting were performed as described in
Materials and Methods. The membrane was first blotted
with an Ab to activated ERKs (A) and then reblotted with
an Ab to activated MEK (B). Cells were treated with the
inhibitors for 5.0 min at 37°C and then stimulated with
1.0 mM fMLP for 3.0 min. Lane a is for unstimulated
neutrophils. Lane b is for stimulated cells. Lanes c–f are
for stimulated cells treated with the following: 50 mM
W-7 (c), 50 mM W-5 (d), 15 mM TFP (e), and 15 mM
PMZ (f).
FIGURE 7. A pathway for the activation of Paks during stimulation of
neutrophils with fMLP. Occupation of the fMLP receptor (FPR) results in
disassociation of the pertussis toxin sensitive heterotrimeric G protein cou-
pled to this receptor to yield the a-GTP-bound and bg-subunits. Activation
of PI-PLC b by these subunits results in an increase in cytosolic Ca21,
activation of CaM and Src-family tyrosine kinases (Src). The exact link
between the Ca21/CaM complex and Src is not known. Src and PI 3-Kg are
thought to be required for activation of the GEF for Rac. Unproven path-
ways are indicated by dashed lines. FPR, Formyl peptide receptor; IP3,
inositol(1,4,5)-trisphosphate.
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with other effector proteins (44). Differences in assay conditions
(e.g., detergents, incubation times) can alter the amount of “pro-
tected Rac” and could account for some of the discrepancies in the
literature. A corollary of this situation is that the pull-down assay
for Rac and the renaturation assay for Pak may monitor different
populations of Rac.
It is noteworthy that KN-93, but not KN-92, blocked activation
of the Paks in neutrophils (Fig. 2D) but did not effect the activation
of Rac (Fig. 4D) or O22 release (see Results). Thus, KN-93 blocks
activation of Pak by a mechanism different from that of W-7 and
TFP. KN-93 does not bind to CaM but competes for the CaM
binding site on CaM-PK (40). The concentrations of KN-93 that
blocked activation of Paks (Fig. 2) were similar to those that in-
hibit CaM-PK in other cell types (40, 42). The question as to
whether a CaM-PK may be involved in the activation of Pak (e.g.,
by direct phosphorylation?) is currently under investigation.
In summary, we provide evidence that the Ca2/CaM complex
plays a major role in activation of the Paks and ERKs in neutro-
phils through stimulation of their upstream effectors Rac and Ras.
Identifying the direct target(s) of CaM in these pathways may
markedly increase our knowledge of the GEFs in neutrophils that
control a variety of cellular responses.
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